ROCKVILLE, Md., Jan. 17, 2017 /PRNewswire/ -- While momentum around immunotherapies for cancer continues to build, the high cost of these therapies places them at the center of debate about how best to define and measure value in cancer care. As these therapies are increasingly integrated into practice, all stakeholders—providers, patients, payers, and manufacturers—need to keep pace with emerging developments and real-world challenges. A new white paper from the Association of Community Cancer Centers (ACCC) Institute for Clinical Immuno-Oncology (ICLIO) highlights immunotherapy research from 2016, emerging policy issues and challenges that may impact the future of immuno-oncology in practice, and ICLIO resources to support the multidisciplinary cancer care team in delivering immunotherapies for cancer.
The white paper, Immuno-Oncology: There's More to Discover, spotlights top-level concerns for the future of immunotherapy in practice, including:
- Payer and coverage policies continue to pose barriers to access to immunotherapies for cancer. Thus, providers in the community have an ongoing need for education and strategies to effectively address prior authorization requirements, claims denials, and expanded access to clinical trials.
- Patients are driving discussions about expanded access to immunotherapies. Direct-to-consumer and other media advertising is fueling interest in immunotherapies. At the same time, this consumer interest is requiring ongoing education so that consumers understand the patient populations for whom these therapies are appropriate and to ensure that both providers and patients are equipped to discuss the benefits and risks of a particular immunotherapy.
- Recognition and management of immune-related adverse events (irAEs) continue to create additional expense and resource requirements across the continuum of care. Community providers are likely to see increasing challenges in this area as new indications and new combination therapies are approved by the FDA. Education on how to leverage operational assets and marshal resources to adequately recognize and manage irAEs will continue to be important.
- Alternative payment models (APMs) focused on value-based reimbursement must include input and buy-in from the oncology community. There is concern that APMs could be developed without oncologist input, peer review, or evidence concerning immunotherapies for cancer. Ultimately, APMs will need to create and utilize quality measures that promote innovation rather than simply drive down costs, because it is often challenging to identify what a therapy's value is until providers use it in a real-world context.
As immunotherapy for cancer continues to evolve, clinical, administrative, and infrastructural operations education is increasingly important. Immuno-Oncology: There's More to Discover describes the robust support and resources ICLIO offers to meet these educational needs. ICLIO is uniquely positioned as the sole provider of comprehensive education dedicated to empowering and preparing multidisciplinary cancer care teams in the community for immuno-oncology. Coming in 2017 to ICLIO's growing portfolio of resources:
- Tailored support and education through the ground-breaking ICLIO Visiting Experts program. This newly-launched educational program is designed to directly address many of the challenges noted in the ICLIO white paper. Through an application process, select ACCC Cancer Program members will receive customized, on-site training from a veteran team of multidisciplinary providers experienced in integration of immunotherapy into practice.
- Role-specific e-learning modules for oncologists, nurses/nurse navigators, and pharmacists. These online courses, developed by leading experts in the field of immuno-oncology, bring practical, real-world information to support these providers in delivery of immunotherapy to patients in their communities.
- Tumor-specific toolkits for immunotherapy in lung cancer, melanoma, and emerging tumor types. These ICLIO toolkits will feature multimedia content curated by leading experts comprising the interdisciplinary team needed to delivery immunotherapy.
Download the ICLIO white paper and view all ICLIO resources at accc-iclio.org.
About the Institute for Clinical Immuno-Oncology
An institute of the Association of Community Cancer Centers (ACCC), the Institute for Clinical Immuno-Oncology (ICLIO) is the only initiative to prepare multidisciplinary cancer care providers for the complex implementation of immuno-oncology in the community setting.
ICLIO is made possible by a charitable donation from Bristol-Myers Squibb and supported by an educational grant from Merck & Co., Inc. For more information, visit the ICLIO website at accc-iclio.org. Follow ICLIO on Twitter @ACCC_ICLIO.
About the Association of Community Cancer Centers
The Association of Community Cancer Centers (ACCC) is the leading advocacy and education organization for the multidisciplinary cancer care team. More than 23,000 cancer care professionals from over 2,500 hospitals and practices nationwide are affiliated with ACCC. Providing a national forum for addressing issues that affect community cancer programs, ACCC is recognized as the premier provider of resources for the entire oncology care team. Our members include medical and radiation oncologists, surgeons, cancer program administrators and medical directors, senior hospital executives, practice managers, pharmacists, oncology nurses, radiation therapists, social workers, and cancer program data managers. For more information, visit ACCC's website at accc-cancer.org. Follow us on Facebook, Twitter, LinkedIn, and read our blog, ACCCBuzz.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/institute-for-clinical-immuno-oncology-white-paper-highlights-the-challenges-progress-and-priorities-in-immunotherapy-300392169.html
SOURCE Association of Community Cancer Centers